US regulators allow emergency use of drug that has helped Covid-19 patients recover 'four days' faster

The FDA has permitted the emergency drug treatment
REUTERS
Ellena Cruse1 May 2020

An experimental medicine that appears to help coronavirus patients recover faster has been given the green light for emergency use by US regulators.

It is the first drug shown to help fight Covid-19, which has killed more than 230,000 people worldwide.

The Food and Drug Administration (FDA) acted after preliminary results from a government-sponsored study showed that Gilead Sciences’s remdesivir shortened the time to recovery by 31 per cent, or about four days on average.

The study of 1,063 hospital patients is the largest and most strict test of the drug and included a comparison group that received just usual care so remdesivir’s effects could be rigorously evaluated.

President Donald Trump announced the FDA’s action at the White House.

Those given the drug were able to leave the hospital in 11 days on average versus 15 days for the comparison group. The drug also might be reducing deaths, although that is not certain from the partial results revealed so far.

The National Institutes of Health’s Dr Anthony Fauci said the drug would become a new standard of care for severely ill Covid-19 patients like those in this study.

President Donald Trump announced the news at the White House
Reuters

The drug has not been tested on people with milder illness, and currently is given through an IV in a hospital.

Gilead has said it would donate its currently available stock of the drug and is ramping up production to make more.

No drugs are approved now for treating coronavirus, and remdesivir will still need formal approval.

The FDA previously gave emergency use authorisation to a malaria drug, hydroxychloroquine, after President Donald Trump repeatedly promoted it as a possible treatment for Covid-19.

No large high-quality studies have shown the drug to work for that, however, and it has significant safety concerns.

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in